What it is
Tirzepatide acts on GIP and GLP-1 receptors. MOVA educational content does not imply that a particular product or formulation will be prescribed.
Treatment information
Tirzepatide: an educational overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It must not be described as GLP-2. Certain tirzepatide products are FDA-approved for specific indications, but treatment decisions require individual clinical review.
What review covers
A clinician considers your full assessment, contraindications, medication list, allergies, symptoms, pregnancy status, and follow-up needs.
What to discuss
Ask about serious and common risks, interactions, warning symptoms, monitoring, alternatives, follow-up, and the exact product being considered.
Your next step
Start with a secure health assessment
A licensed clinician must independently review your information before any treatment plan or prescription can be offered.
Begin assessmentIf a compounded option is ever offered, it is not FDA-approved and must not be described as a generic equivalent or as identical to a brand-name drug. Availability and appropriateness depend on the prescribing clinician and dispensing pharmacy.